LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Buch ; Dissertation / Habilitation: Effekt einer frühen immun-chemotherapeutischen Behandlung mit Fludarabin, Cylophosphamid und Rituximab versus Beobachtung bei Patienten mit chronischer lymphatischer Leukämie und prognostischem Hochrisikoprofil

    Groß-Ophoff-Müller, Carolin / Hallek, Michael / Cornely, Oliver Andreas

    2022  

    Körperschaft Universitätsklinikum Köln / Klinik I für Innere Medizin
    Verfasserangabe vorgelegt von Carolin Groß-Ophoff-Müller ; 1. Gutachter: Universitätsprofessor Dr. med. M.J. Hallek, 2. Gutachter: Universitätsprofessor Dr. med. O.A. Cornely ; aus dem Zentrum für Innere Meidzin der Universität zu Köln, Klinik und Poliklinik für Innere Medizin I
    Thema/Rubrik (Code) 610
    Sprache Deutsch
    Umfang 54 Blätter, Diagramme
    Erscheinungsort Köln
    Erscheinungsland Deutschland
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Dissertation, Universität zu Köln, 2021
    HBZ-ID HT021299190
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    SignaturLeihstatusStandort
    2022 D 166 bestellbar zur Ausleihe Magazin

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Digital decision support for structural improvement of melanoma tumor boards: using standard cases to optimize workflow.

    Hoier, David / Groß-Ophoff-Müller, Carolin / Franklin, Cindy / Hallek, Michael / von Stebut, Esther / Elter, Thomas / Mauch, Cornelia / Kreuzberg, Nicole / Koll, Philipp

    Journal of cancer research and clinical oncology

    2024  Band 150, Heft 3, Seite(n) 115

    Abstract: Purpose: Choosing optimal cancer treatment is challenging, and certified cancer centers must present all patients in multidisciplinary tumor boards (MDT). Our aim was to develop a decision support system (DSS) to provide treatment recommendations for ... ...

    Abstract Purpose: Choosing optimal cancer treatment is challenging, and certified cancer centers must present all patients in multidisciplinary tumor boards (MDT). Our aim was to develop a decision support system (DSS) to provide treatment recommendations for apparently simple cases already at conference registration and to classify these as "standard cases". According to certification requirements, discussion of standard cases is optional and would thus allow more time for complex cases.
    Methods: We created a smartphone query that simulated a tumor conference registration and requested all information needed to provide a recommendation. In total, 111 out of 705 malignant melanoma cases discussed at a skin cancer center from 2017 to 2020 were identified as potential standard cases, for which a digital twin recommendation was then generated by DSS.
    Results: The system provided reliable advice in all 111 cases and showed 97% concordance of MDT and DSS for therapeutic recommendations, regardless of tumor stage. Discrepancies included two cases (2%) where DSS advised discussions at MDT and one case (1%) with deviating recommendation due to advanced patient age.
    Conclusions: Our work aimed not to replace clinical expertise but to alleviate MDT workload and enhance focus on complex cases. Overall, our DSS proved to be a suitable tool for identifying standard cases as such, providing correct treatment recommendations, and thus reducing the time burden of tumor conferences in favor for the comprehensive discussion of complex cases. The aim is to implement the DSS in routine tumor board software for further qualitative assessment of its impact on oncological care.
    Mesh-Begriff(e) Humans ; Melanoma/therapy ; Workflow ; Medical Oncology
    Sprache Englisch
    Erscheinungsdatum 2024-03-08
    Erscheinungsland Germany
    Dokumenttyp Journal Article
    ZDB-ID 134792-5
    ISSN 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
    ISSN (online) 1432-1335
    ISSN 0171-5216 ; 0084-5353 ; 0943-9382
    DOI 10.1007/s00432-024-05627-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.10: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia.

    Langerbeins, Petra / Groß-Ophoff-Müller, Carolin / Herling, Carmen D

    Oncology research and treatment

    2016  Band 39, Heft 1-2, Seite(n) 18–24

    Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and usually affects the elderly patient. More than 50% of CLL cases are diagnosed at an early disease stage, often as an incidental lymphocytosis found in a routine blood screen. ... ...

    Abstract Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and usually affects the elderly patient. More than 50% of CLL cases are diagnosed at an early disease stage, often as an incidental lymphocytosis found in a routine blood screen. For about 40 years, the classifications according to Binet or Rai have been the hands-on staging systems to stratify patients in daily clinical practice. An increasing molecular understanding of the disease and the identification of strong prognostic markers, such as genetic lesions in TP53, have urged clinical scientists to create new scoring systems that improve prognostic risk assessment and treatment allocation. Until today, studies on early treatment interventions in asymptomatic patients using single chemo- or combined chemoimmunotherapy have failed to demonstrate a survival benefit. However, improved risk stratification tools integrating molecular disease features and the availability of new targeted drugs with attractive efficacy and limited toxicity might open new possibilities to re-investigate early treatment in well-defined clinical settings in the future.
    Mesh-Begriff(e) Animals ; Biomarkers, Tumor/genetics ; Early Detection of Cancer/methods ; Evidence-Based Medicine ; Genetic Markers/genetics ; Genetic Predisposition to Disease/genetics ; Genetic Testing/methods ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/genetics ; Leukemia, Lymphocytic, Chronic, B-Cell/therapy ; Molecular Diagnostic Techniques/methods ; Neoplasm Staging ; Outcome Assessment (Health Care)/methods ; Polymorphism, Single Nucleotide/genetics ; Precision Medicine/methods ; Risk Assessment/methods ; Treatment Outcome
    Chemische Substanzen Biomarkers, Tumor ; Genetic Markers
    Sprache Englisch
    Erscheinungsdatum 2016
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2760274-6
    ISSN 2296-5262 ; 2296-5270
    ISSN (online) 2296-5262
    ISSN 2296-5270
    DOI 10.1159/000443013
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1414: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

    Langerbeins, Petra / Groß-Ophoff-Müller, Carolin / Herling, Carmen D.

    Oncology Research and Treatment

    2016  Band 39, Heft 1-2, Seite(n) 18–24

    Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and usually affects the elderly patient. More than 50% of CLL cases are diagnosed at an early disease stage, often as an incidental lymphocytosis found in a routine blood screen. ... ...

    Körperschaft Department I of Internal Medicine, Center for Integrated Oncology (CIO) Cologne-Bonn, University of Cologne, Germany
    Abstract Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and usually affects the elderly patient. More than 50% of CLL cases are diagnosed at an early disease stage, often as an incidental lymphocytosis found in a routine blood screen. For about 40 years, the classifications according to Binet or Rai have been the hands-on staging systems to stratify patients in daily clinical practice. An increasing molecular understanding of the disease and the identification of strong prognostic markers, such as genetic lesions in TP53, have urged clinical scientists to create new scoring systems that improve prognostic risk assessment and treatment allocation. Until today, studies on early treatment interventions in asymptomatic patients using single chemo- or combined chemoimmunotherapy have failed to demonstrate a survival benefit. However, improved risk stratification tools integrating molecular disease features and the availability of new targeted drugs with attractive efficacy and limited toxicity might open new possibilities to re-investigate early treatment in well-defined clinical settings in the future.
    Schlagwörter Prognostic factor ; Deferred treatment ; Early disease ; Chronic lymphocytic leukemia
    Sprache Englisch
    Erscheinungsdatum 2016-01-22
    Verlag S. Karger GmbH
    Erscheinungsort Freiburg, Germany
    Dokumenttyp Artikel
    Anmerkung Review Article
    ZDB-ID 2760274-6
    ISSN 2296-5262 ; 2296-5270
    ISSN (online) 2296-5262
    ISSN 2296-5270
    DOI 10.1159/000443013
    Datenquelle Karger Verlag

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1414: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Risk-Adapted Therapy in Early-Stage Chronic Lymphocytic Leukemia

    Langerbeins, Petra / Groß-Ophoff-Müller, Carolin / Herling, Carmen D.

    Oncology Research and Treatment

    2016  Band 39, Heft 1-2, Seite(n) 18–24

    Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and usually affects the elderly patient. More than 50% of CLL cases are diagnosed at an early disease stage, often as an incidental lymphocytosis found in a routine blood screen. ... ...

    Abstract Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and usually affects the elderly patient. More than 50% of CLL cases are diagnosed at an early disease stage, often as an incidental lymphocytosis found in a routine blood screen. For about 40 years, the classifications according to Binet or Rai have been the hands-on staging systems to stratify patients in daily clinical practice. An increasing molecular understanding of the disease and the identification of strong prognostic markers, such as genetic lesions in TP53, have urged clinical scientists to create new scoring systems that improve prognostic risk assessment and treatment allocation. Until today, studies on early treatment interventions in asymptomatic patients using single chemo- or combined chemoimmunotherapy have failed to demonstrate a survival benefit. However, improved risk stratification tools integrating molecular disease features and the availability of new targeted drugs with attractive efficacy and limited toxicity might open new possibilities to re-investigate early treatment in well-defined clinical settings in the future.© 2016 S. Karger GmbH, Freiburg
    Schlagwörter Chronic lymphocytic leukemia ; Prognostic factor ; Deferred treatment ; Early disease
    Sprache Englisch
    Verlag S. Karger Verlag für Medizin und Naturwissenschaften GmbH
    Erscheinungsort Freiburg
    Erscheinungsland Germany
    Dokumenttyp Artikel ; Online
    ZDB-ID 2760274-6
    ISSN 2296-5262 ; 2296-5270 ; 2296-5270
    ISSN (online) 2296-5262
    ISSN 2296-5270
    DOI 10.1159/000443013
    Datenquelle Karger Verlag

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 1414: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Impact of induction chemotherapy on objective and self-perceived cognitive performance in patients suffering from hematological disorders.

    Zimmer, Philipp / Hillebrand, Philipp / Wolf, Florian / Joisten, Niklas / Walzik, David / Hardt, Luca / Großek, Anja / Hartig, Philipp / Kierdorf, Fiona / Belz, Maximilian / Tinschmann, Malina / Kiesl, David / Bloch, Wilhelm / Groß-Ophoff-Müller, Carolin / Hallek, Michael / Böll, Boris / Oberste, Max / Elter, Thomas

    Leukemia & lymphoma

    2021  Band 62, Heft 10, Seite(n) 2526–2530

    Mesh-Begriff(e) Breast Neoplasms ; Cognition ; Cognition Disorders ; Cognitive Dysfunction ; Female ; Hematologic Diseases ; Humans ; Induction Chemotherapy
    Sprache Englisch
    Erscheinungsdatum 2021-04-21
    Erscheinungsland United States
    Dokumenttyp Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1913151
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2997: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  7. Artikel ; Online: Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.

    Herling, Carmen D / Cymbalista, Florence / Groß-Ophoff-Müller, Carolin / Bahlo, Jasmin / Robrecht, Sandra / Langerbeins, Petra / Fink, Anna-Maria / Al-Sawaf, Othman / Busch, Raymonde / Porcher, Raphael / Cazin, Bruno / Dreyfus, Brigitte / Ibach, Stefan / Leprêtre, Stéphane / Fischer, Kirsten / Kaiser, Florian / Eichhorst, Barbara / Wentner, Clemens-Martin / Hoechstetter, Manuela A /
    Döhner, Hartmut / Leblond, Veronique / Kneba, Michael / Letestu, Remi / Böttcher, Sebastian / Stilgenbauer, Stephan / Hallek, Michael / Levy, Vincent

    Leukemia

    2020  Band 34, Heft 8, Seite(n) 2038–2050

    Abstract: We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic leukemia (CLL). Eight hundred patients with ... ...

    Abstract We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic leukemia (CLL). Eight hundred patients with untreated-stage Binet A disease were enrolled as intent-to-treat population and assessed for four prognostic markers: lymphocyte doubling time <12 months, serum thymidine kinase >10 U/L, unmutated IGHV genes, and unfavorable cytogenetics (del(11q)/del(17p)/trisomy 12). Two hundred and one patients with ≥2 risk features were classified as high-risk CLL and 1:1 randomized to receive either immediate therapy with 6xFCR (Hi-FCR, 100 patients), or to be observed according to standard of care (Hi-W&W, 101 patients). The overall response rate after early FCR was 92.7%. Common adverse events were hematological toxicities and infections (61.0%/41.5% of patients, respectively). After median observation time of 55.6 (0-99.2) months, event-free survival was significantly prolonged in Hi-FCR compared with Hi-W&W patients (median not reached vs. 18.5 months, p < 0.001). There was no significant overall survival benefit for high-risk patients receiving early FCR therapy (5-year OS 82.9% in Hi-FCR vs. 79.9% in Hi-W&W, p = 0.864). In conclusion, although FCR is efficient to induce remissions in the Binet A high-risk CLL, our data do not provide evidence that alters the current standard of care "watch and wait" for these patients.
    Mesh-Begriff(e) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/administration & dosage ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Male ; Middle Aged ; Neoplasm, Residual ; Prospective Studies ; Rituximab/administration & dosage ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives
    Chemische Substanzen Rituximab (4F4X42SYQ6) ; Cyclophosphamide (8N3DW7272P) ; Vidarabine (FA2DM6879K) ; fludarabine (P2K93U8740)
    Sprache Englisch
    Erscheinungsdatum 2020-02-18
    Erscheinungsland England
    Dokumenttyp Clinical Trial, Phase III ; Comparative Study ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-020-0747-7
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 2295: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang